Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2019 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
REGENERON PHARMACEUTICALS | 8 | Q3 2017 | 12.5% |
ABBOTT LABS | 8 | Q3 2017 | 9.4% |
REGENERON PHARMACEUTICALS | 8 | Q3 2017 | 7.1% |
POTASH CORP SASK INC | 8 | Q3 2017 | 2.2% |
GW PHARMACEUTICALS PLC | 8 | Q3 2017 | 4.1% |
GW PHARMACEUTICALS PLC | 8 | Q3 2017 | 2.2% |
INOTEK PHARMACEUTICALS CORP | 8 | Q3 2017 | 1.3% |
SAREPTA THERAPEUTICS INC | 8 | Q3 2017 | 2.9% |
REGENERON PHARMACEUTICALS | 8 | Q3 2017 | 2.9% |
VALEANT PHARMACEUTICALS INTL | 8 | Q3 2017 | 2.0% |
View FT Options LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2017-11-13 |
13F-HR | 2017-08-11 |
13F-HR | 2017-05-12 |
13F-HR | 2017-02-10 |
13F-HR | 2016-11-10 |
13F-HR | 2016-08-12 |
13F-HR | 2016-05-09 |
13F-HR | 2016-02-05 |
View FT Options LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.